NOT-TR-21-023: Notice of Correction to Application Types Allowed for RFA-TR-21-010 Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases (U44 Clinical Trial Required)

Notice of Correction to Application Types Allowed for RFA-TR-21-010 “Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases (U44 Clinical Trial Required)”

Notice Number:

NOT-TR-21-023

Key Dates

Release Date:

March 8, 2021

Related Announcements

RFA-TR-21-010 - Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases (U44 Clinical Trial Required)

Issued by

National Center for Advancing Translational Sciences (NCATS)

Purpose

The purpose of this Notice is to correct the Application Types Allowed for RFA-TR-21-010, Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases (U44 Clinical Trial Required)

The following sections of RFA-TR-21-010 are being corrected:

Part 2. Full Text of Announcement, Section II. Award Information

Application Types Allowed

Currently reads:

New (Phase I, Fast-Track)
New (SBIR Direct Phase II)

Revised to read:

New (Fast-Track)
New (SBIR Direct Phase II)

All other aspects of the FOA are unchanged.

Inquiries

Please direct all inquiries to:

P.J. Brooks, Ph.D.
National Center for Advancing Translational Sciences (NCATS)
Telephone: 301-443-0513
Email: [email protected]

Lili Portilla, M.P.A.
National Center for Advancing Translational Sciences (NCATS)
Telephone: 301-827-7170
Email: [email protected]